An Open-Label, Phase 1/1B, Single-Agent Study of RXDX-105 In Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Ignyta, Inc.

Protocol Number
RXDX-105-01

To Learn More Call
201-510-0910